Antibodies
18 September 2014
CYRAMZA™ In Combination With Paclitaxel Significantly Improves Overall Survival In Second-Line Gastric Cancer Patients17 September 2014
Roche to present latest oncology advances during ESMO 2014 Congress17 September 2014
Gilead Announces Data From Phase 2 Study of Simtuzumab for Previously Untreated Pancreatic Cancer16 September 2014
EYLEA® (aflibercept) Injection Receives FDA Breakthrough Therapy Designation for Diabetic Retinopathy in Patients with Diabetic Macular Edema16 September 2014
Roche initiates phase III trials for lampalizumab, first potential treatment for geographic atrophy (GA)16 September 2014
EPIRUS’ Remicade® Biosimilar Receives Final Approvals in India16 September 2014
New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density15 September 2014
Kolltan Cancer Study Results for KTN3379, Targeting ErbB3, Support Evaluating Combinations with Targeted Therapies12 September 2014
Lilly Announces CYRAMZA™ Phase III Second-Line Colorectal Cancer Trial Meets Primary Endpoint of Overall Survival11 September 2014
At Four Years, Treatment Effect Maintained in More Than Two-Thirds of Patients Who Received Genzyme’s Lemtrada in Pivotal Studies10 September 2014
Biotest completes recruitment in Phase IIb study (TREAT 2b) of Tregalizumab (BT-061) in patients with rheumatoid arthritis8 September 2014
Molecular Templates Announces FDA Approval of Investigational New Drug Application for CD20 Internalizing Immunotoxin MT-37248 September 2014
Roche’s RoACTEMRA receives EU approval for use in patients with early rheumatoid arthritis (RA)5 September 2014
TRACON Pharmaceuticals Initiates Phase 2 Clinical Trial of TRC105 in Patients With Soft Tissue Sarcoma5 September 2014
FDA Removes Partial Clinical Hold on OncoMed’s Ipafricept5 September 2014
Merck Receives Accelerated Approval of KEYTRUDA® (pembrolizumab), the First FDA-Approved Anti-PD-1 Therapy3 September 2014
Visterra to Present Data at ICAAC on VIS513, Its Humanized Monoclonal Antibody That Targets a Conserved Site on the Dengue Virus E Protein3 September 2014
GeNeuro Successful Phase 2a Clinical Study Reinforces Novel Approach to Treat Multiple SclerosisNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
SubscribeNewsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
SubscribeFeatured reports